TISIDB

Summary
Symbol	SCYL1
Name	SCY1-like, kinase-like 1
Aliases	HT019; GKLP; NKTL; TAPK; TEIF; MGC78454; teratoma-associated tyrosine kinase; telomerase transcriptional ele ......
Chromosomal Location	11q11-q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Endoplasmic reticulum-Golgi intermediate compartment Golgi apparatus, cis-Golgi network Note=Localized to the Endoplasmic reticulum-Golgi intermediate and cis-Golgi in an ARF1-independent manner.; SUBCELLULAR LOCATION: Isoform 1: Cytoplasm. Note=Cytoplasmic throughout the cell cycle.; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Note=Cytoplasmic throughout the cell cycle.; SUBCELLULAR LOCATION: Isoform 3: Cytoplasm. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Note=Cytoplasmic during interphase and centrosomal during mitosis, it localizes to the centrosomes in a microtubule-independent manner.; SUBCELLULAR LOCATION: Isoform 6: Nucleus
Domain	PF00069 Protein kinase domain
Function	Regulates COPI-mediated retrograde protein traffic at the interface between the Golgi apparatus and the endoplasmic reticulum (PubMed:18556652). Involved in the maintenance of the Golgi apparatus morphology (PubMed:26581903). Has no detectable kinase activity in vitro (PubMed:18556652). ; FUNCTION: Isoform 6 acts as transcriptional activator. It binds to three different types of GC-rich DNA binding sites (box-A, -B and -C) in the beta-polymerase promoter region. It also binds to the TERT promoter region.

> Gene Ontology [ TOP ]
Biological Process	GO:0006890 retrograde vesicle-mediated transport, Golgi to ER GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0048193 Golgi vesicle transport
Molecular Function	GO:0004713 protein tyrosine kinase activity GO:0045296 cadherin binding GO:0050839 cell adhesion molecule binding GO:0098631 protein binding involved in cell adhesion GO:0098632 protein binding involved in cell-cell adhesion GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component	GO:0005793 endoplasmic reticulum-Golgi intermediate compartment GO:0005798 Golgi-associated vesicle GO:0005801 cis-Golgi network GO:0005913 cell-cell adherens junction GO:0030117 membrane coat GO:0030120 vesicle coat GO:0030126 COPI vesicle coat GO:0030135 coated vesicle GO:0030137 COPI-coated vesicle GO:0030659 cytoplasmic vesicle membrane GO:0030660 Golgi-associated vesicle membrane GO:0030662 coated vesicle membrane GO:0030663 COPI-coated vesicle membrane GO:0048475 coated membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	SCYL1
Name	SCY1-like, kinase-like 1
Aliases	HT019; GKLP; NKTL; TAPK; TEIF; MGC78454; teratoma-associated tyrosine kinase; telomerase transcriptional ele ......
Chromosomal Location	11q11-q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SCYL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SCYL1
Name	SCY1-like, kinase-like 1
Aliases	HT019; GKLP; NKTL; TAPK; TEIF; MGC78454; teratoma-associated tyrosine kinase; telomerase transcriptional ele ......
Chromosomal Location	11q11-q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SCYL1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: -1.88; FDR: 0.04220	Resistant to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SCYL1
Name	SCY1-like, kinase-like 1
Aliases	HT019; GKLP; NKTL; TAPK; TEIF; MGC78454; teratoma-associated tyrosine kinase; telomerase transcriptional ele ......
Chromosomal Location	11q11-q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SCYL1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.135	0.542
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.319	0.891
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.005	0.998
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.045	0.886
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.149	0.947
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.089	0.976
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.046	0.901
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.004	0.998
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.083	0.963
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.077	0.965
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.056	0.983
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.007	0.891

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SCYL1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	0	7.4	0.0709
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	0	7.4	0.096
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	18.8	-7.7	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	33.3	-33.3	0.258
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	7.4	0.5	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	7.7	-3.2	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	12.5	7.1	5.4	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SCYL1
Name	SCY1-like, kinase-like 1
Aliases	HT019; GKLP; NKTL; TAPK; TEIF; MGC78454; teratoma-associated tyrosine kinase; telomerase transcriptional ele ......
Chromosomal Location	11q11-q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SCYL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SCYL1
Name	SCY1-like, kinase-like 1
Aliases	HT019; GKLP; NKTL; TAPK; TEIF; MGC78454; teratoma-associated tyrosine kinase; telomerase transcriptional ele ......
Chromosomal Location	11q11-q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SCYL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SCYL1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SCYL1
Name	SCY1-like, kinase-like 1
Aliases	HT019; GKLP; NKTL; TAPK; TEIF; MGC78454; teratoma-associated tyrosine kinase; telomerase transcriptional ele ......
Chromosomal Location	11q11-q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SCYL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SCYL1
Name	SCY1-like, kinase-like 1
Aliases	HT019; GKLP; NKTL; TAPK; TEIF; MGC78454; teratoma-associated tyrosine kinase; telomerase transcriptional ele ......
Chromosomal Location	11q11-q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SCYL1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SCYL1
Name	SCY1-like, kinase-like 1
Aliases	HT019; GKLP; NKTL; TAPK; TEIF; MGC78454; teratoma-associated tyrosine kinase; telomerase transcriptional ele ......
Chromosomal Location	11q11-q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SCYL1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SCYL1
Name	SCY1-like, kinase-like 1
Aliases	HT019; GKLP; NKTL; TAPK; TEIF; MGC78454; teratoma-associated tyrosine kinase; telomerase transcriptional ele ......
Chromosomal Location	11q11-q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SCYL1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting SCYL1.

ID	Name	Drug Type	Targets	#Targets
DB05036	Grn163l	Small Molecule	PTGES3, SCYL1, SMG6, TERT	4

Browse SCYL1